The Introduction of Generic Aromatase Inhibitors and Treatment Adherence Among Medicare D Enrollees

Journal of the National Cancer Institute

Volumn 107, Issue 8, 2015, Pages

  Neuner, Joan M ^a   Kamaraju, Sailaja ^a   Charlson, John A ^a   Wozniak, Erica M ^a   Smith, Elizabeth C ^a   Biggers, Alana ^a   Smallwood, Alicia J ^a   Laud, Purushottam W ^a   Pezzin, Liliana E ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; GENERIC DRUG; NITRILE; TRIAZOLE DERIVATIVE;

AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER SURGERY; COHORT ANALYSIS; CONFOUNDING VARIABLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG COST; FEMALE; HEALTH PROGRAM; HUMAN; LONGITUDINAL STUDY; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MEDICARE; MEDICATION COMPLIANCE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT COMPLIANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; QUASI EXPERIMENTAL STUDY; VERY ELDERLY; BREAST NEOPLASMS; CONTROLLED CLINICAL TRIAL (TOPIC); ECONOMICS; EVALUATION STUDY; POVERTY; STATISTICS AND NUMERICAL DATA; UNITED STATES;

AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; COHORT STUDIES; DRUG COSTS; DRUGS, GENERIC; EVALUATION STUDIES AS TOPIC; FEMALE; HUMANS; MEDICARE; MEDICATION ADHERENCE; NITRILES; NON-RANDOMIZED CONTROLLED TRIALS AS TOPIC; POVERTY; TRIAZOLES; UNITED STATES;

EID: 84939643031     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv130     Document Type: Article

References (39)

1. Weingart S, Brown E, Bach P, et al. NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw. 2008;6:S1-S14.
2. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-816.
3. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
4. Early Breast Cancer Trialists' Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-784.
5. Gibson L, Lawrence D, Dawson C, et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2009;(4):1-121.
6. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
7. Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21(4):602-606.
8. Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26(4):556-562.
9. Kimmick G, Anderson R, Camacho F, et al. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol. 2009;27(21):3445-3451.
10. Ziller V, Kalder M, Albert U-S, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol. 2009;20(3):431-436.
11. Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology. 2006;71(1-2):1-9.
12. Lash TL, Fox MP, Westrup JL, et al. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99(2):215-220.
13. Partridge AH, Avorn J, Wang PS, et al. Adherence to therapy with oral anti-neoplastic agents. J Natl Cancer Inst. 2002;94(9):652-661.
14. McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008;99(11):1763-1768.
15. Barron TI, Connolly R, Bennett K, et al. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer. 2007;109(5):832-839.
16. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529-537.
17. Neugut AI, Subar M, Wilde ET, et al. Association between prescription copayment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29(18):2534-2542.
18. Riley GF, Warren JL, Harlan LC, et al. Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D. Medicare Medicaid Res Rev. 2011;1(4):E1-E26.
19. Nattinger AB, Laud PW, Bajorunaite R, et al. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res. 2004;39(6 Pt 1):1733-1749.
20. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Affair. 2008;27(1):103-112.
21. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105-116.
22. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med. 2007;357(7):673-681.
23. Schneeweiss S, Patrick AR, Pedan A, et al. The effect of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits. Health Affairs. 2009;28(2):w305-w316.
24. Gu Q, Zeng F, Patel BV, et al. Part D coverage gap and adherence to diabetes medications. Am J Manag Care. 2009;16(12):911-918.
25. Fung V, Mangione CM, Huang J, et al. Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes. Health Serv Res. 2010;45(2):355-375.
26. Dusetzina SB, Winn AN, Abel GA, et al. Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia. J Clin Oncol. 2014;32(4):306-311.
27. Hershman DL, Tsui J, Meyer J, et al. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer. J Natl Cancer Inst. 2014;106(11):1-9.
28. Loewenstein G, Asch DA, Volpp KG. Behavioral economics holds potential to deliver better results for patients, insurers, and employers. Health Affairs. 2013;32(7):1244-1250.
29. Sedjo RL, Cox ER. Lowering copayments: impact of simvastatin patent expiration on patient adherence. Am J Manag Care. 2008;14(12):813-818.
30. Hoadley J, Summer L, Hargrave E, Cubanski J, Neuman T. Analysis of Medicare Prescription Drug Plans in 2012 and Key Trends Since 2006. The Henry J. Kaiser Foundation, 2012. http://kaiserfamilyfoundation.files.wordpress.com/2013/01/8357.pdf. Accessed November 2012.
31. nd Session. H. R. 4872, The Health Care and Education Reconciliation Act. Washington: Government Printing Office, 2010.
32. Weaver C. Closing Medicare drug gap helps Democrats sell reform. Kaiser Health News. 2010. http://www.kaiserhealthnews.org/stories/2010/march/29/health-reform-doughnut-hole.aspx. Accessed January 2015.
33. Alpern JD, Stauffer WM, Kesselheim AS. High-cost generic drugs - implications for patients and policymakers. N Engl J Med. 2014;371(20):1859-1862.
34. Perrone M. Soaring generic drug prices draw Senate scrutiny. Associated Press. Nov 20, 2014. http://news.yahoo.com/soaring-generic-drug-pricesdraw-senate-scrutiny-141933064--finance.html. Accessed January 2015.
35. Yen TWF, Czypinski LK, Sparapani RA, et al. Socioeconomic factors associated with adjuvant hormone therapy use in older breast cancer survivors. Cancer. 2011;117(2):398-405.
36. Li P, McElligott S, Bergquist H, et al. Effect of the Medicare Part D coverage cap on medication use among patients with hypertension and hyperlipidemia. Ann Intern Med. 2012;156(11):776-784.
37. Tamblyn R, Eguale T, Huang A, et al. The incidence and determinants of primary nonadherence with prescribed medication in primary care: a cohort study. Ann Intern Med. 2014;160(7):441-450.
38. Kripalani S, Yao X, Haynes R. Interventions to enhance medication adherence in chronic medical conditions: A systematic review. Arch Intern Med. 2007;167(6):540-549.
39. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. J Am Med Assoc. 2002;288(22):2868-2879, correction.